Companies Dominating the Rift Valley Fever Treatment Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.,
- Siemens Healthcare GmbH
- Pfizer Inc.
- Eli Lilly and Company
- Cipla Limited
- Kemwell Biopharma Private Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of rift valley fever treatment is estimated at USD 2.06 billion.
The rift valley fever treatment market size was over USD 1.97 billion in 2024 and is poised to exceed USD 3.86 billion by 2037, growing at over 5.3% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of RVF and increasing awareness about the disease will boost the market growth.
North America industry is expected to dominate majority revenue share of 35% by 2037, due to rising substantial prevalence of RVF in the region.
The major players in the market are Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Eli Lilly and Company, and others.
